Latest Virus-like particle Stories
DURHAM, NC and QUEBEC CITY, QC, July 24, 2012 /PRNewswire/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced the successful completion of a key milestone under an agreement with the Defense Advanced Research Projects Agency (DARPA). The milestone was the production of at least 10 million doses of H1N1...
QUEBEC CITY, June 14, 2012 /PRNewswire/ - Medicago Inc. (TSX: MDG) (OTCQX: MDCGF), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that Mr. Pierre Labbé, Vice-President and Chief Financial Officer of Medicago, will be presenting at the Bloom Burton & Co. Healthcare Investment Conference. The conference is being held at the Toronto Board of...
QUEBEC CITY, May 14, 2012 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that the Company will host an Investor Day event on May 30, 2012, at the Indigo Hotel, 151 Tatum Drive, Durham, North Carolina The meeting, which also will be webcast live, will begin promptly at 12:30 p.m. Eastern Time and end...
QUEBEC CITY, May 11, 2012 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced its operational and financial results for the first quarter ended March 31, 2012. The Company's financial statements and management report are available at www.sedar.com and at www.medicago.com. "In the first quarter of 2012, we...
QUEBEC CITY, May 10, 2012 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that Mr. Mike Wanner, Executive Vice President, Operations, will be presenting at the 13th Annual BioEquity Europe Conference. The conference is being held May 15-16, 2012, at the Frankfurt Marriott Hotel in Frankfurt, Germany. ...
QUEBEC CITY, April 12, 2012 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, announced today that Chief Executive Officer Andy Sheldon was named "CEO of the Year" at the recently held World Vaccine Congress in Washington, D.C. The Vaccine Industry Excellence (ViE) Awards recognize the outstanding achievements of vaccine...
QUEBEC CITY, March 29, 2012 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced its operational and financial results for the fourth quarter and year ended December 31, 2011. The Company's financial statements and management report are available at www.sedar.com and at www.medicago.com. The Company also...
Mitsubishi Tanabe Pharma Identified as Lead Investor in September 2011 Equity Financing QUEBEC CITY, March 27, 2012 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), announced the establishment of a strategic alliance with Mitsubishi Tanabe Pharma Corporation (MTPC) through the execution of a Master Research...
QUEBEC CITY, QC, March 9, 2012 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that Mr. Andy Sheldon, President and Chief Executive Officer of Medicago, will be presenting at the 24(th) Annual Roth Growth Stock Conference. The conference is being held March 11-14, 2012 at the Ritz Carlton Laguna Niguel...
RALEIGH, NC and QUEBEC CITY, Feb. 13, 2012 /PRNewswire/ - Medicago USA Inc., a wholly owned subsidiary of Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it has received the fourth milestone payment of US$3.56 million from the Defense Advanced Research Projects Agency ("DARPA"). This is part of the potential US$21 million...
